|
May 2
|
QGEN or RGEN: Which Is the Better Value Stock Right Now?
|
|
May 2
|
Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare
|
|
May 1
|
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Arguably The Most Innovative Biopharma Company I’ve Seen In The Last Two Decades’
|
|
May 1
|
Jim Cramer on Repligen Corporation (RGEN): ‘I’m Not Quite Ready to Stick My Neck Out on This One’
|
|
Apr 30
|
RGEN Q1 Earnings Call: Repligen Delivers Above-Consensus Revenue, Raises Sales Outlook Amid Tariff Uncertainty
|
|
Apr 30
|
Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y
|
|
Apr 30
|
Repligen Corp (RGEN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
|
|
Apr 30
|
Q1 2025 Repligen Corp Earnings Call
|
|
Apr 29
|
Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates
|
|
Apr 29
|
Repligen (NASDAQ:RGEN) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds Expectations
|
|
Apr 29
|
Repligen: Q1 Earnings Snapshot
|
|
Apr 29
|
Repligen Reports First Quarter 2025 Financial Results
|
|
Apr 28
|
Repligen (RGEN) Q1 Earnings: What To Expect
|
|
Apr 25
|
3 Healthcare Stocks That Concern Us
|
|
Apr 10
|
Repligen (RGEN): Buy, Sell, or Hold Post Q4 Earnings?
|
|
Apr 8
|
Repligen Appoints Jacob Johnson As Vice President Investor Relations
|
|
Apr 8
|
Repligen (RGEN) Moves 3.7% Higher: Will This Strength Last?
|
|
Mar 12
|
Q4 Earnings Recap: Azenta (NASDAQ:AZTA) Tops Drug Development Inputs & Services Stocks
|
|
Mar 11
|
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
|
|
Feb 21
|
Repligen's Q4 Earnings Beat Estimates, Revenues In Line
|